|
Online Database of Chemicals from Around the World | 产品搜索 | 产品提交 | 产品推广 |
网站主页 >> 化工产品目录 >> Crenolanib>> 市场分析报告 |
Crenolanib市场分析报告 |
|
Gastrointestinal Stromal Tumor Therapeutics Market Size, Trends, Analysis, and Outlook By Drug (Imatinib, Ripretinib, Crenolanib, Regorafenib, Avapritinib, Sunitinib, Entrectinib, Larotrectinib), By Therapy (Targeted therapy, Chemotherapy, Radiation therapy ), By Distribution Channel (Hospital pharmacies, Retail pharmacies, Online pharmacies), By Route of Administration (Oral, Parenteral), by Region, Country, Segment, and Companies, 2024-2030 ... Therapeutics market By Drug (Imatinib, Ripretinib, Crenolanib, Regorafenib, Avapritinib, Sunitinib, Entrectinib, Larotrectinib ... FLT3 Inhibitor Market Report: Trends, Forecast and Competitive Analysis ... ($B) Shipment Analysis from 2017 to 2028]: Crenolanib Dovitinib SKLB1028 FLT3 Inhibitor Market ... , sorafenib, and others), pipeline product (crenolanib, dovitinib, and SKLB1028), and region ... Global Systemic Mastocytosis Treatment Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028 ... AK-002 BLU-285 Brentuximab Vedotin Crenolanib Besylate Cromolyn Sodium Others Market ... Acute Myeloid Leukaemia:KOL Insight ... quizartinib (Daiichi Sankyo) gilteritinib (Astellas) crenolanib (Arog Pharmaceuticals) ivosidenib (Agios Pharmaceuticals ... Systemic Mastocytosis Treatment Market - Global Outlook and Forecast 2022-2028 ... (%) AK-002 BLU-285 Brentuximab Vedotin Crenolanib Besylate Cromolyn Sodium Others Global ... Acute Myeloid Leukemia (AML) Therapeutics: Market Research Report This report analyzes the worldwide markets for Acute Heart Failure (AHF) Therapeutics in US$ Thousand. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the ... Gastrointestinal Stromal Tumors - Pipeline Insight, 2021 ... Nilotinib HQP1351 PDR001 Ponatinib MEK162 Crenolanib besylate XmAb18087 TNO155 DNX-2440 ... Soft Tissue Sarcoma - Pipeline Insight, 2021 ... Vigil Tazemetostat Olaratumab Doxorubicin Aldoxorubicin Crenolanib TAS-116 Ganitumab Selinexor NBTXR3 ... Acute Myeloid Leukemia - Pipeline Review, 2019 ... Cytarabine Ivosidenib Guadecitabine Volasertib Daunorubicin Crenolanib AB8939 Sapacitabine Liposomal Annamycin MGD006 ... Glioblastoma Multiforme - Pipeline Review - 2019 ... MM-398 ARC-100 AV0113 Cotara Crenolanib SGT-53 Endostatin ANG1005 Platelet-derived growth factor receptor antagonists - Pipeline Insight, 2022 ... Vorolanib Axitinib MGD 1509 Regorafenib Crenolanib AGN-151200 Sorafenib nanoparticle formulation ... Global PDGFR Inhibitors Market, Drug Sales & Clinical Trials Insight 2026 ... several potential PGFR inhibitors including Crenolanib, Tovetumab, Seralutinib, ARRY-768, CP-673451 ... Fms-like tyrosine kinase 3 inhibitors - Pipeline Insight, 2022 ... : small molecule anti-cancer therapeutics Crenolanib Olverembatinib PHI-101 Midostaurin Cabozantinib ... Gliosarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Gliosarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gliosarcoma - Drugs In Development, 2022, provides an ... 2023-2028 Global and Regional Systemic Mastocytosis Treatment Industry Status and Prospects Professional Market Research Report Standard Version ... : AK-002 BLU-285 Brentuximab Vedotin Crenolanib Besylate Cromolyn Sodium Others By Applications ... Global Systemic Mastocytosis Treatment Market Research Report 2024(Status and Outlook) ... ) AK-002 BLU-285 Brentuximab Vedotin Crenolanib Besylate Cromolyn Sodium Others Market ... Gastrointestinal Stromal Tumor Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 The 7 major gastrointestinal stromal tumor markets reached a value of US$ 493.6 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 810.2 Million by 2034, exhibiting a growth rate (CAGR) of 4.61% during 2024-2034. The ... Pontine Glioma (DIPG):Drug Development Pipeline Study, H1 2018 The most comprehensive pipeline review “Diffuse Intrinsic Pontine Glioma (DIPG)- Drug Development Pipeline Study” provides in-depth analysis and update information on Diffuse Intrinsic Pontine Glioma (DIPG) pipeline drugs. Current status of all the drugs ... |